EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sangamo Therapeutics's enterprise value is $99.91 Mil.
Sangamo Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $18.76 Mil. Therefore, Sangamo Therapeutics's EV-to-Revenue for today is 5.33.
The historical rank and industry rank for Sangamo Therapeutics's EV-to-Revenue or its related term are showing as below:
LTS:0R1D'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.22 Med: 8.64 Max: 55.21
Current: 5.33
During the past 13 years, the highest EV-to-Revenue of Sangamo Therapeutics was 55.21. The lowest was -0.22. And the median was 8.64.
LTS:0R1D's EV-to-Revenue is ranked better than 60.69% of 1038
companies
in the Biotechnology industry
Industry Median: 8.145
vs LTS:0R1D: 5.33
Sangamo Therapeutics EV-to-Revenue Historical Data
The historical data trend for Sangamo Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sangamo Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Sangamo Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sangamo Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Sangamo Therapeutics's EV-to-Revenue falls into.
Sangamo Therapeutics's current Enterprise Value is $99.91 Mil.
Sangamo Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangamo Therapeutics's share price for today is $0.5916.
Sangamo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangamo Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Sangamo Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Sangamo Therapeutics (LTS:0R1D) Business Description
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0R1D has been successfully added to your 